申请人:Novartis AG
                            
                            
                                公开号:US08153669B2
                            
                            
                                公开(公告)日:2012-04-10
                            
                            
Compounds of formula (I), in salt or zwitterionic form, wherein J, L, M, R1, R2, R3, R4 and R5 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.
                            式(I)的化合物,以盐或双离子形式存在,其中J、L、M、R1、R2、R3、R4和R5的含义如规范中所示,可用于治疗由肌动蛋白M3受体介导的疾病。还描述了含有这些化合物的制药组合物和制备这些化合物的过程。